Sanofi's proposed type 1 diabetes treatment sotagliflozin may provide an important test of the power of personalized medicine and patient-physician decision-making.
Sanofi and development partner Lexicon Pharmaceuticals Inc. have proposed sotagliflozin, an SGLT 1 and SLGT 2 inhibitor, as an adjunct to insulin to improve glycemic control in adults with type 1 diabetes mellitus
Sotagliflozin, proposed trade name Zynquista, provided patients in clinical trials more control of glucose levels and fewer spikes. However, the increased risk of diabetic ketoacidosis (DKA) is substantial and appeared to be across all patients based on the study data